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Summary 
Background Serum CA125 concentration often rises several months before clinical or symptomatic relapse in women 
with ovarian cancer. In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the beneﬁ ts of early 
treatment on the basis of increased CA125 concentrations compared with delayed treatment on the basis of 
clinical recurrence.
Methods Women with ovarian cancer in complete remission after ﬁ rst-line platinum-based chemotherapy and a 
normal CA125 concentration were registered for this randomised controlled trial. Clinical examination and CA125 
measurement were done every 3 months. Patients and investigators were masked to CA125 results, which were 
monitored by coordinating centres. If CA125 concentration exceeded twice the upper limit of normal, patients were 
randomly assigned (1:1) by minimisation to early or delayed chemotherapy. Patients and clinical sites were informed of 
allocation to early treatment, and treatment was started as soon as possible within 28 days of the increased CA125 
measurement. Patients assigned to delayed treatment continued masked CA125 measurements, with treatment 
commencing at clinical or symptomatic relapse. All patients were treated according to standard local practice. The 
primary outcome was overall survival. Analysis was by intention to treat. This study is registered, ISRCTN87786644.
Findings 1442 patients were registered for the trial, of whom 529 were randomly assigned to treatment groups and were 
included in our analysis (265 early, 264 delayed). With a median follow-up of 56·9 months (IQR 37·4–81·8) from 
randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a diﬀ erence in overall survival between 
early and delayed treatment (HR 0·98, 95% CI 0·80–1·20, p=0·85). Median survival from randomisation was 25·7 months 
(95% CI 23·0–27·9) for patients on early treatment and 27·1 months (22·8–30·9) for those on delayed treatment. 
Interpretation Our ﬁ ndings showed no evidence of a survival beneﬁ t with early treatment of relapse on the basis of a 
raised CA125 concentration alone, and therefore the value of routine measurement of CA125 in the follow-up of 
patients with ovarian cancer who attain a complete response after ﬁ rst-line treatment is not proven. 
Funding UK Medical Research Council and the European Organisation for Research and Treatment of Cancer.
Introduction 
Early detection and treatment of cancer is commonly 
believed to improve outcomes for patients. This idea is 
the main rationale for regular follow-up after completion 
of cancer treatment. However, data from the few 
randomised studies that have investigated timing of 
therapy1–5 are conﬂ icting with respect to early treatment 
for patients presenting with metastatic disease, and no 
randomised trials have adequately addressed timing of 
treatment for recurrent cancer.6,7 
The serum tumour marker CA125 is used for initial 
diagnosis and monitoring of response to chemotherapy 
for epithelial ovarian cancer. Regular measurement 
during follow-up is one of the best examples in oncology 
of a test that can detect recurrence of cancer months 
before symptoms or signs occur.8–12 Although most 
women can expect a good response and improved 
survival after chemotherapy for their ﬁ rst recurrence,13 
this treatment is rarely curative and has side-eﬀ ects. 
Concerns about CA125 testing and the implications of 
raised CA125 concentration are major sources 
of anxiety. 
A woman with a rising CA125 concentration, who 
remains well, without symptoms or signs of recurrent 
disease, presents a major management dilemma.14 
Because of this issue, practice varies widely in terms of 
whether or not regular CA125 measurements are done 
and in the timing of initiation of second-line 
chemotherapy. We therefore undertook a randomised 
trial with the aim of establishing the beneﬁ ts of early 
treatment on the basis of increased serum CA125 
concentrations compared with delayed treatment on the 
basis of clinical recurrence. 
Methods
Trial design and patients
The British Medical Research Council (MRC) OV05 and 
European Organisation for Research and Treatment of 
Cancer (EORTC) 55955 trials were collaborative trials 
undertaken with a joint trial management group and 
monitored by a single independent data monitoring 
committee. All statistical analyses were done at the MRC 
Clinical Trials Unit. Ethics approval for MRC OV05 was 
obtained from the London multicentre research ethics 
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committee and at each site. EORTC 55955 received local 
ethics approval at each site. 
Women with histologically conﬁ rmed epithelial ovarian, 
fallopian tube, or serous primary peritoneal cancer (based 
on local pathology) in complete clinical remission after 
completion of ﬁ rst-line platinum-based chemotherapy 
with a normal CA125 concentration were eligible for trial 
registration. Written informed consent was obtained. 
Procedures 
After registration, trial visits occurred every 3 months 
and included physical and gynaecological examinations, 
ultrasound and radiological examinations according to 
local practice, quality of life assessment, and a CA125 
blood test. CA125 testing was done in local laboratories 
that agreed to mask results to clinicians and patients, 
participate in local quality assurance schemes, and send 
results to coordinating centres. If CA125 concentration 
increased to twice the site upper limit of normal, patients 
were randomly assigned to early treatment, with the 
clinical site notiﬁ ed of the randomisation, or to delayed 
treatment. Patients were informed of allocation to early 
treatment, and treatment was started as soon as possible 
within 28 days after an unmasked conﬁ rmatory CA125 
concentration twice the upper limit of normal. If a 
woman was assigned to delayed treatment, the site was 
not notiﬁ ed, and masked follow-up continued until 
clinical recurrence was detected and delayed treatment 
started. Quality of life was assessed before each 
chemotherapy cycle until the end of third-line treatment 
with the EORTC QLQ-C30 questionnaire.15 Choice of 
chemotherapy was according to standard local practice. 
Randomisation and masking
Randomisation to early or delayed treatment groups 
(1:1 ratio) was done independently by each coordinating 
centre. The method of minimisation was used with the 
stratiﬁ cation factors: International Federation of 
Gynecology and Obstetrics (FIGO) stage (I vs II vs III vs 
IV); ﬁ rst-line chemotherapy (single agent platinum vs 
platinum combination without taxane vs platinum-
taxane combination vs other); time from completion of 
ﬁ rst-line chemotherapy to raised CA125 concentration 
(<6 vs 6–11 vs 12–24 vs >24 months); age (MRC OV05 at 
randomisation, EORTC 55955 at registration; <30 vs 
30–55 vs 56–65 vs >65 years); and site. CA125 results 
were masked to sites and patients until randomisation 
to early treatment or until clinical recurrence for those 
in the delayed treatment group.
Statistical analysis
The primary outcome measure was overall survival 
calculated from date of randomisation to date of last 
follow-up or death from any cause. At the time of analysis, 
survivors were censored at the date they were last known 
to be alive. Secondary outcomes were: time to second-
line chemotherapy (calculated from date of randomisation 
to date of initiation of second-line chemotherapy, women 
who did not receive second-line chemotherapy were 
censored at the date of last contact); time to third-line 
treatment or death (calculated from date of randomisation 
to date of starting third-line treatment or death, whichever 
occurred ﬁ rst, survivors without treatment censored at 
the last contact); quality of life with duration of good 
quality of life in the global health score (deﬁ ned as 
improved or no more than a 10% decrease from 
Figure 1: Trial proﬁ le
ULN=upper limit of normal. 
Patients with ovarian cancer in complete
remission after ﬁrst-line platinum-based
chemotherapy and normal CA125
concentrations
1442 patients registered, masked CA125
measured every 3 months (MRC OVO5,
n=1144; EORTC 55955, n=298)
529 randomised (MRC OVO5, n=436; 
         EORTC 55955, n=93)
913 not randomised
421 (29%) CA125 less than twice
ULN at trial closure
60 (4%) progressed with CA125
more than twice ULN
215 (15%) progressed without
CA125 more than twice ULN
59 (4%) died
132 (9%) withdrew
26 (2%) other/unknown
reasons
265 assigned early treatment 264 assigned delayed treatment
11 did not receive treatment
2 patient or clinical decision
1 too ill for treatment
4 randomised in error
1 died shortly after randomisation
3 unknown
254 (96%) started second-line
chemotherapy
78 (29%) single agent platinum
40 (15%) combination platinum,
no taxane
91 (34%) platinum and taxane
15 (6%) taxane without platinum
28 (11%) other
2 (1%) unknown treatment
6 lost to follow-up
265 analysed for primary outcome 264 analysed for primary outcome
15 lost to follow-up
233 (88%) started second-line
chemotherapy
67 (25%) single agent platinum
34 (13%) combination platinum,
no taxane
102 (39%) platinum and taxane
9 (3%) taxane without platinum
15 (6%) other
6 (3%) unknown treatment
31 did not receive treatment
7 no clinical relapse
4 patient or clinical decision
3 too ill for treatment
4 randomised in error
6 withdrew/lost to follow-up
3 died shortly after randomisation
3 died (other cause of death)
1 unknown
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prerandomisation score); and time of ﬁ rst global health-
related deterioration (deﬁ ned as more than 10% decrease 
from prerandomisation score or death). 
The trial was initially designed to detect a 10% 
improvement in 2-year overall survival from 5% delayed 
treatment to 15% early treatment. However, in 2002 (with 
191 women randomly assigned to treatment groups) the 
2-year overall survival of women assigned to delayed 
treatment was estimated to be closer to 40%. The 
independent data monitoring committee (without 
reference to outcome data from the early treatment 
group) recommended that sample-size estimations were 
revised to give a range of registrations and randomisations 
required to give suﬃ  cient power. Revised estimates 
(continuing to target a 10–15% absolute improvement), 
which included a range of 2-year survival estimates in the 
delayed treatment group from 40% to 50%, required 
530–1400 registrations and 350–650 randomisations and 
were included in a protocol amendment. After the trial 
closed to registrations in August, 2005, with 1442 registered 
women, the randomisation rate fell. In February, 2007, 
when the study had been open for longer than 10 years 
and 510 patients had been randomly assigned to treatment 
groups, the trial management group carefully considered 
trial closure options. At this time the estimated 2-year 
overall survival in the delayed-treatment group was 54%. 
To detect a 10% absolute improvement with 5% 
signiﬁ cance level and 85% power, 345 events were 
needed. This target was assessed as achievable and was 
agreed by the trial management group as the target 
number of events for the primary analysis. All women 
were followed up until randomisation or an event that 
precluded randomisation and for survival. Clinical follow-
up with masked CA125 measurements continued for 
6 months after close of randomisation.
Stata (version 10.1) was used for all analyses. The 
primary analysis was the log-rank test, stratiﬁ ed by 
MRC versus EORTC, applied to compare the Kaplan-
Meier survival curves for all time-to-event outcome 
measures. Cox model sensitivity analyses estimating 
the treatment eﬀ ect and adjusting for stratiﬁ cation and 
prognostic factors were done for overall survival. All 
women were included in the analysis, which was by 
intention to treat. All p values are two-sided. To adjust 
for imbalances in follow-up between the two groups, 
curtailing was used for main analyses of time-to-event 
outcome measures, by censoring data at 5 years from 
randomisation for MRC OV05 and 3 years for EORTC 
55955. Additional sensitivity analyses were done for 
uncurtailed data. 
This study is registered, ISRCTN87786644.
Role of the funding source
The MRC and EORTC reviewed and approved the 
study design. The study sponsors, the MRC for OV05 
and EORTC for 55955, had no role in the conduct of the 
study or in writing of this report. The writing 
committee had full access to all study data and had 
responsibility for the decision to submit for publication.
Results
MRC OV05 started in May, 1996, and EORTC 55955 in 
May, 1999, closing to registrations on Aug 31, 2005, with 
Early treatment (n=265) Delayed treatment (n=264)
Age
<30 years 0 0
30–55 years 81 (31%) 89 (34%)
56–65 years 110 (42%) 93 (35%)
>65 years 74 (28%) 82 (31%)
Median (years) 60 (53–66) 61 (53–68)
FIGO stage
IA 5 (2%) 0
IB 1 (<1%) 2 (1%)
IC 15 (6%) 18 (7%)
II 30 (11%) 28 (11%)
III 181 (68%) 182 (69%)
IV 33 (12%) 34 (13%)
Histology
Serous 172 (65%) 154 (58%)
Endometrioid 30 (11%) 31 (12%)
Mucinous 9 (3%) 8 (3%)
Clear cell 11 (4%) 9 (3%)
Undiﬀ erentiated 22 (8%) 16 (6%)
Adenocarcinoma, not otherwise speciﬁ ed 14 (5%) 39 (15%)
Other 3 (1%) 3 (1%)
Unknown/missing 4 (2%) 4 (2%)
WHO performance status
0 182 (69%) 198 (75%)
1 78 (29%) 65 (25%)
2 4 (2%) 1 (<1%)
3 1 (<1%) 0
First-line chemotherapy
Single agent platinum 104 (39%) 105 (39%)
Combination platinum (no taxane) 16 (6%) 16 (6%)
Platinum and taxane based 143 (54%) 143 (54%)
Other 2 (1%) 0
Time to registration after completion of ﬁ rst-line chemotherapy
<3 months 211 (80%) 205 (78%)
4 months 19 (7%) 17 (6%)
5 months 5 (2%) 18 (7%)
6 months 7 (3%) 5 (2%)
>6 months 23 (9%) 19 (7%)
Time to doubling of CA125 concentration after completion of ﬁ rst-line chemotherapy
<6 months 53 (20%) 51 (19%)
6–11 months 87 (33%) 89 (34%)
12–24 months 69 (26%) 67 (25%)
>24 months 52 (20%) 52 (20%)
Unknown 4 (2%) 5 (2%)
Data are number (%) or median (IQR). FIGO=International Federation of Gynecology and Obstetrics.
Table 1: Characteristics at registration of all patients randomly assigned to treatment groups
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1442 women registered (1144 MRC, 298 EORTC; ﬁ gure 1). 
Women were registered from 59 centres across the UK, 
Spain, Norway, the Netherlands, France, Russia, Belgium, 
Ireland, Austria, and South Africa. Baseline characteristics 
of registered women are shown in the webappendix. All 
women had conﬁ rmation of remission (normal CA125 
concentration and no evidence of disease after surgery and 
ﬁ rst-line chemotherapy, radiologically conﬁ rmed in all but 
two patients), 94% (1362 women) within 3 months before 
registration. Median time from completion of ﬁ rst-line 
chemotherapy to registration was 1·7 months (IQR 1·0–
3·2), with 1066 (74%) women registered within 3 months. 
492 registered women had an event during follow-up that 
excluded them from randomisation (ﬁ gure 1). When 
randomisation closed (March 31, 2008), 421 (29%) registered 
women were still in clinical remission with a normal CA125 
concentration and were eligible for randomisation. Median 
survival from end of ﬁ rst-line chemotherapy to last follow-
up or death for all women registered in the trial was 
70·8 months (95% CI 64·1–78·0). 
Between Feb 26, 1997, and March 31, 2008, 529 women 
were randomly assigned to treatment groups (37% of 
those registered; 265 to early and 264 to delayed 
chemotherapy). The randomised treatment groups were 
well balanced for baseline characteristics at registration 
(table 1). The median time from registration to 
randomisation was 9·1 months (IQR 5·5–18·2). Time 
from completion of ﬁ rst-line chemotherapy to increase 
of CA125 concentration to twice the upper limit of 
normal was well balanced between the groups; 104 (20%) 
women had a rise within 6 months after ﬁ rst-line 
chemotherapy, 176 (33%) between 6 and 12 months, and 
240 (45%) after 12 or more months. Randomisation was 
within 28 days of the date of the CA125 concentration 
rising to twice the upper limit of normal for 483 (91%) 
participants (webappendix). 
When data were locked for the primary analysis on 
Feb 16, 2009, with a median follow-up of 56·9 months 
(IQR 37·4–81·8) from randomisation, 370 (70%) women 
assigned to treatment groups had died (186 early, 
184 delayed treatment). Almost all deaths were disease 
related (97% early, 96% delayed; table 2). There was no 
evidence of a diﬀ erence in overall survival (ﬁ gure 2; 
hazard ratio [HR] 0·98, 95% CI 0·80–1·20; p=0·85; HR <1 
in favour of delayed treatment group; table 3). Median 
survival from randomisation was 25·7 months (95% CI 
23·0–27·9) in patients receiving early treatment and 
27·1 months (22·8–30·9) in those receiving delayed. 
2-year survival was 53·7% in patients allocated early 
treatment and 54·7% in those receiving delayed 
treatment—a diﬀ erence (delayed minus early) at 2 years 
of 0·7% (95% CI for diﬀ erence –5·8 to 7·6). Cox models 
adjusted for stratiﬁ cation and prognostic factors (table 3) 
did not change the overall result, showing the unadjusted 
results to be robust. Censored and uncensored analyses 
also gave the same result (table 3). 
Women assigned to early treatment started 
chemotherapy 4·8 months (95% CI 3·6–5·3) earlier than 
those allocated delayed treatment (ﬁ gure 2), 179 (68%) 
within 1 month from randomisation, and 241 (91%) 
within 3 months. Type of second-line chemotherapy 
regimen was well balanced—a platinum-taxane 
combination was administered to 91 (34%) women 
assigned to early treatment and 102 (39%) of those 
assigned delayed (a diﬀ erence of 11 women), and single 
agent platinum to 78 (29%) of those receiving early 
treatment and 67 (25%) of those allocated delayed 
(ﬁ gure 1). A higher proportion of women in the early 
treatment group (169, 64%) received six or more 
chemotherapy cycles than in the delayed treatment group 
(134, 51%). 21 women assigned early treatment and 
14 delayed treatment underwent secondary surgery. More 
women assigned to delayed treatment (31, 12%) had no 
second-line chemotherapy (compared with only 11 [4%] 
in the early treatment group), in seven (3%) patients 
because they had not clinically relapsed at the time of 
data locking. Details of other reasons why second-line 
chemotherapy was not received are shown in ﬁ gure 1. 
After second-line chemotherapy, 177 women (67%) 
assigned to early and 142 women (54%) to delayed 
treatment started third-line treatment (table 2)—a 
diﬀ erence of 13% (95% CI for diﬀ erence 4·7–21·3). The 
median time from randomisation to third-line treatment 
or death was 12·5 months (95% CI 11·4–13·3) in the 
early-treatment group and 17·1 months (15·6–19·1) in 
the delayed-treatment group, showing that women 
assigned to early treatment needed further treatment for 
clinical progression on average 4·6 months (95% CI 
4·2–5·8) earlier than those assigned to delayed (ﬁ gure 2, 
table 3; HR 0·69, 95% CI 0·57–0·83; p=0·0001).
Early treatment 
(n=265)
Delayed treatment 
(n=264)
All (n=529)
Overall survival
Alive 79 (30%) 80 (30%) 159 (30%)
Dead 186 (70%) 184 (70%) 370 (70%)
Cause of death
Disease related 180 177 357
Disease and treatment related 0 2 2
Treatment related 1 0 1
Other* 4 5 9
Unknown 1 0 1
Median survival 25·7 (23·0–27·9) 27·1 (22·8–30·9) 25·9 (23·5–28·3)
Third-line treatment or death
Alive, no third-line treatment 30 (11%) 35 (13%) 65 (12%)
Alive, received third-line treatment 39 (15%) 35 (13%) 74 (14%)
Died, received third-line treatment 138 (52%) 107 (41%) 245 (46%)
Died, no third-line treatment 58 (22%) 87 (33%) 145 (27%)
Data are number (%) or median (95% CI). *Other causes of death were: bronchopneumonia, pulmonary embolism, cardiac 
arrest and pulmonary embolism, cerebral vascular accident, bronchopneumonia and ischaemic heart disease, renal failure, 
chronic obstructive pulmonary disease, and two patients with no details speciﬁ ed but classiﬁ ed as other cause of death. 
Table 2: Summary of events
See Online for webappendix
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There was no evidence of treatment interactions in 
exploratory analyses to establish whether the eﬀ ect of 
early compared with delayed treatment varied in 
subgroups of women deﬁ ned by type of ﬁ rst-line 
chemotherapy (single agent platinum vs platinum-taxane 
combination; p value for interaction=0·07), age (30–55 vs 
56–65 vs >65 years; p=0·65), FIGO stage (p=0·20), and 
WHO performance status (0 vs 1; p=0·51; ﬁ gure 3). There 
was no detectable diﬀ erence in treatment eﬀ ect before 
and after June, 2003, after the shift to platinum-taxane 
combinations as second-line chemotherapy (p=0·90). 
The eﬀ ect of early compared with delayed treatment did 
not diﬀ er between women who were randomly assigned 
to treatment groups soon after completion of ﬁ rst-line 
treatment compared with later (<6 vs 6–11 vs 12–24 vs 
>24 months from completion of ﬁ rst-line treatment to 
randomisation; p=0·34). All treatment interaction 
analyses were prespeciﬁ ed in the statistical analysis plan, 
Figure 2: Main outcome measures
Kaplan-Meier plots for (A) overall survival, (B) second-line chemotherapy, (C) third-line treatment or death, and (D) ﬁ rst deterioration in Global Health Score or death. 
(E) Duration of time spent with good Global Health Score during the ﬁ rst 2 years from randomisation. HR=hazard ratio.
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with the exception of timing of second-line treatment 
and time from ﬁ rst-line treatment to randomisation, 
which were ad hoc. 
Median time spent with good global health score was 
7·2 months (95% CI 5·3–9·3) for women assigned to 
early and 9·2 months (6·4–10·5) for those assigned to 
delayed treatment (ﬁ gure 2). Time from randomisation to 
ﬁ rst deterioration in global health score or death (ﬁ gure 2) 
was shorter (median 3·2 months, 95% CI 2·4–4·3) in the 
early group compared with delayed (5·8 months, 4·4–8·5; 
HR 0·71, 95% CI 0·58–0·88; p=0·002). Subgroup analyses 
of individual components of the QLQ-C30 subscales 
showed deterioration in score sooner in the early group 
than in the delayed group for almost all subscales, and 
there was evidence of signiﬁ cant disadvantages for role, 
emotional, social, and fatigue subscales (table 4) with early 
treatment. Since the QLQ-C30 questionnaire asks about 
symptoms only in the previous week, and the forms were 
completed just before each course of chemotherapy, this 
method could underestimate any reduction in quality of 
life due to chemotherapy.
Discussion
Our results challenge the widespread belief that earlier 
treatment for recurrent cancer must be better, particularly 
for cancers for which recurrent disease is disseminated 
and curative options few. They provide no evidence that 
early initiation of chemotherapy because of a rising CA125 
concentration improves survival or quality of life compared 
with delaying of chemotherapy until signs or symptoms of 
recurrence for women with complete radiological and 
biochemical remission after ﬁ rst-line chemotherapy for 
ovarian cancer. There are no other randomised controlled 
trials addressing this question (see panel). With such a 
large amount of information, 70% of patients having died, 
a late eﬀ ect of treatment is very unlikely. One explanation 
for our ﬁ ndings could be that the lead time between CA125 
rise and clinical recurrence, particularly for rapidly 
growing, possibly more chemosensitive tumours, might 
be too short for early introduction of chemotherapy to 
have a beneﬁ cial eﬀ ect. However, we found no evidence 
that early chemotherapy had greater eﬀ ect in those with a 
short time from end of ﬁ rst-line chemotherapy to 
randomisation (ﬁ gure 3). 
The median lead time between randomisation with 
CA125 rise and second-line chemotherapy for clinical 
recurrence was 4·8 months. If more recently proposed 
criteria of an early signal of CA125 recurrence were used19 
the proportion of patients with a rise in CA125 might have 
been higher, more patients might have been randomised, 
with those starting chemotherapy in the early-treatment 
group having a greater lead time. The lead time might 
also have been greater if CA125 had been measured more 
frequently. If we had seen any beneﬁ t from earlier 
treatment, one could anticipate that a longer lead time 
could give greater beneﬁ ts. However, since there was no 
evidence that earlier chemotherapy resulted in survival or 
quality of life beneﬁ t, increasing of the lead time would 
result in more women living with the anxiety associated 
with an increased CA125 concentration for longer. 
First-line chemotherapy had to be platinum-based, but 
because the type of chemotherapy might vary according 
to timing of relapse and previous experience with 
diﬀ erent treatments (eg, neuropathy), choice of second-
line regimen was left to the treating clinician. There was 
a small diﬀ erence in chemotherapy regimens given for 
relapse; 34% of those in the early-treatment group 
received platinum-taxane combination therapy at relapse, 
compared with 39% of those receiving delayed treatment. 
This small diﬀ erence (11 patients), which could favour 
delayed treatment, might have arisen as a result of the 
Hazard ratio 
(95% CI)
Log-rank 
p value
Unadjusted 0·98 (0·80–1·20) 0·85
Adjusted
For stratiﬁ cation factors* 0·99 (0·80–1·22) ··
For prognostic factors† 0·98 (0·79–1·21) ··
For stratiﬁ cation and prognostic factors 1·01 (0·82–1·25) ··
Sensitivity analyses‡ 1·01 (0·82–1·23) 0·96
*Age, International Federation of Gynecology and Obstetrics stage, ﬁ rst-line 
chemotherapy, time from completion of ﬁ rst-line chemotherapy to doubling of 
CA125 concentration, and country. †Histology, WHO performance status, and 
time from doubling of CA125 concentration to randomisation. ‡Sensitivity 
analyses of non-curtailed data (all follow-up data received, not curtailed at 5 years 
for MRC OV05 and 3 years for EORTC 55955).
Table 3: Hazard ratios for overall survival
Figure 3: Treatment interactions
Data are number of events/number of patients, observed (O) minus expected (E) events, variance, and hazard ratio 
(HR; 95% CI). 
Delayed
treatment
Early
treatment
O-E Variance HR (95% CI)
59/89
65/93
60/82
13/20
17/28
130/182
24/34
74/105
95/143
134/198
49/65
98/112
70/117
40/46
79/93
42/72
23/53
Age
30–55 years
56–65 years
>65 years
FIGO stage
I
II
III
IV
First-line chemotherapy
Single agent platinum
Platinum and taxane
WHO performance status
0
1
Timing of second-line chemotherapy
Pre-ICON4
Post-ICON4
End of ﬁrst-line treatment to randomisation
<6 months
6–11 months
12–24 months
>24 months
58/81
  75/110
53/74
13/21
14/30
134/181
25/33
81/104
93/143
120/182
61/78
118/139
64/115
44/48
72/88
51/75
19/54
–2·75
3·41
–3·00
0·84
3·33
–1·31
–5·94
–10·78
5·11
1·85
–3·32
–0·74
–1·40
3·65
–1·92
–6·29
3·08
28·86
34·29
27·69
6·42
7·50
65·77
11·20
37·80
46·80
62·97
27·21
53·30
32·64
19·90
37·16
23·07
10·28
0·91 (0·63–1·31)
1·10 (0·79–1·54)
0·90 (0·62–1·30)
1·14 (0·53–2·47)
1·56 (0·76–3·19)
0·98 (0·77–1·25)
0·59 (0·33–1·06)
0·75 (0·55–1·03)
1·12 (0·84–1·49)
1·03 (0·80–1·32)
0·89 (0·61–1·29)
0·99 (0·75–1·29)
0·96 (0·68–1·35)
1·20 (0·77–1·86)
0·95 (0·69–1·31)
0·76 (0·51–1·15)
1·35 (0·73–2·49)
0 0·5 1
Favours delayed Favours early
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Articles
www.thelancet.com   Vol 376   October 2, 2010 1161
change to combination therapy due to the positive results 
of the ICON4/OVAR trial,13 with oncologists wishing to 
treat symptomatic patients more aggressively. However, 
this small diﬀ erence is unlikely to account for the absence 
of beneﬁ t from early treatment, and there was no 
diﬀ erence in the eﬀ ect of treatment before and after 
2003, when ICON4/OVAR was published and clinical 
practice changed.13 There were other diﬀ erences in 
chemotherapy administered that might favour early 
treatment, including more second-line chemotherapy, 
more second-line chemotherapy cycles, and more third-
line treatments.
We have not presented adverse events from individual 
chemotherapy drugs and regimens, since speciﬁ c 
chemotherapy regimens were not mandated. Thus, 
toxic eﬀ ects were not included as a secondary outcome 
measure. However, the safety of individual participants 
in the trial was monitored. Serious adverse events and 
adverse events of all regimens and cause of death were 
reviewed by the independent data monitoring 
committee at each of their meetings, and no safety 
concerns were identiﬁ ed. 
The extent of initial surgery was not recorded and was 
not used as a stratiﬁ cation factor. We were aware of the 
importance of residual disease as a prognostic factor for 
outcome after ﬁ rst-line therapy, but felt that accurate 
surgical data would be diﬃ  cult to obtain for all patients. 
We assumed that, since women who entered this trial 
were in clinical and radiological remission with a normal 
CA125 concentration, a good prognostic group had been 
selected and other prognostic factors derived from earlier 
in patients’ cancer histories would be less important. 
Furthermore, with randomisation of a large number of 
patients, important prognostic factors (both known and 
currently unknown) should be equally distributed 
between the randomised groups. Recent analysis of a 
trial in which extent of residual disease was an inclusion 
criterion has however shown that this factor remains 
signiﬁ cant after ﬁ rst-line therapy.20 We are unable to 
exclude an imbalance in the randomised groups with 
respect to extent of residual disease as an explanation for 
our ﬁ ndings, but suggest that this eﬀ ect is unlikely. 
There was no evidence for a beneﬁ t of early treatment 
in the small group of women presenting with recurrent 
FIGO stage I or II ovarian cancer after adjuvant 
chemotherapy. This result is perhaps not surprising, 
since outcomes after recurrence are similar for women 
with early and advanced initial disease.20 For other 
cancers, cure is sometimes achieved with surgery alone 
or combined with adjuvant therapy, but isolated 
recurrence is rare with ovarian cancer.16,21,22 Patients who 
have complete resection of recurrent ovarian cancer have 
been shown in observational studies to have better 
survival than those with incomplete resection.21,22 
Early detection of relapse by CA125 monitoring could 
be said to lead to more patients being diagnosed at relapse 
with completely resectable disease and having successful 
surgery, and thus longer survival. However, the ability to 
completely resect recurrent tumour could be dependent 
on the biology of the tumour, and not time of detection. 
Contrary to expectations, we have shown that earlier 
chemotherapy had no survival beneﬁ t. Therefore, 
randomised trials showing a beneﬁ t from surgery for 
relapsed disease are essential before CA125 follow-up is 
routinely recommended to trigger radiological detection 
of relapse amenable to surgical treatment. 
For the ﬁ rst time women can be given evidence-based 
advice and can make informed choices about follow-up. 
Women should be informed that there is no evidence of 
Median time to deterioration (months) Hazard ratio (95% CI) p value
Early treatment 
(n=174)
Delayed treatment 
(n=178)
Functional
Physical 8·7 8·6 1·01 (0·75–1·35) 0·94
Role 3·5 6·0 0·74 (0·55–0·98) 0·006
Emotional 4·2 7·5 0·77 (0·58–1·02) 0·02
Cognitive 8·3 10·0 1·01 (0·75–1·36) 0·93
Social 4·1 8·6 0·72 (0·54–0·96) 0·003
Symptom
Fatigue 2·6 6·1 0·64 (0·48–0·85) <0·0001
Nausea and vomiting 5·5 9·2 0·89 (0·66–1·20) 0·31
Pain 5·9 6·3 1·00 (0·75–1·34) 0·97
Dyspnoea 5·2 8·6 0·81 (0·61–1·09) 0·07
Insomnia 4·1 7·9 0·82 (0·62–1·10) 0·08
Appetite loss 7·1 8·2 0·96 (0·72–1·28) 0·69
Constipation 5·8 7·8 0·85 (0·63–1·14) 0·14
Diarrhoea 10·5 11·0 0·99 (0·74–1·32) 0·94
Financial diﬃ  culties 18·6 18·1 0·96 (0·71–1·29) 0·70
EORTC=European Organisation for Research and Treatment of Cancer.
Table 4: Time to ﬁ rst deterioration in quality of life score or death for subscales of EORTC QLQ-C30 
questionnaire
Panel: Research in context 
Systematic review
A Cochrane systematic review protocol16 evaluating follow-up 
strategies in ovarian cancer after ﬁ rst-line treatment was 
assessed as up to date as of July, 2008. We therefore did 
systematic searches repeating the search strategies16 for 
randomised controlled trials from January, 2008, to date 
using Embase,17 Medline, and The Cochrane Central Register 
of Controlled Trials18 including search terms for ovarian 
cancer, follow-up, and CA125. Searches returned 
134 potentially relevant articles; however, no randomised 
controlled trials addressing a similar question to MRC OV05/
EORTC 55955 were found.
Interpretation
MRC OV05/EORTC 55955 is the only randomised controlled 
trial designed to investigate the timing of relapsed treatment 
for ovarian cancer on the basis of CA125 concentration.
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a beneﬁ t from early treatment on the basis of rising 
CA125 concentration, and no deterioration in quality of 
life by delaying chemotherapy. If CA125 concentration 
rises during follow-up, chemotherapy can be safely 
delayed until symptoms or signs of tumour recurrence 
develop. Regular CA125 monitoring might remain a 
requirement in clinical trials, but women might wish 
not to be told their results. Some women, despite these 
trial results, might choose to continue regular CA125 
monitoring as an aid to planning their life. However, 
the results of this trial suggest that they can opt to forgo 
routine CA125 monitoring if their disease is in complete 
remission after ﬁ rst-line treatment, and be reassured 
that if they are worried or develop any signs suspicious 
of tumour relapse they will have rapid access to 
CA125 measurement. 
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